Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Non-Current Deffered Revenue: 2009-2012

Historic Non-Current Deffered Revenue for Amicus Therapeutics (FOLD) over the last 1 years, with Jun 2012 value amounting to $15.7 million.

  • Amicus Therapeutics' Non-Current Deffered Revenue fell 29.75% to $15.7 million in Q2 2012 from the same period last year, while for Jun 2012 it was $15.7 million, marking a year-over-year decrease of 29.75%. This contributed to the annual value of $19.0 million for FY2011, which is 25.90% down from last year.
  • Latest data reveals that Amicus Therapeutics reported Non-Current Deffered Revenue of $15.7 million as of Q2 2012, which was down 9.57% from $17.3 million recorded in Q1 2012.
  • In the past 5 years, Amicus Therapeutics' Non-Current Deffered Revenue registered a high of $43.3 million during Q1 2009, and its lowest value of $15.7 million during Q2 2012.
  • Over the past 3 years, Amicus Therapeutics' median Non-Current Deffered Revenue value was $20.7 million (recorded in 2011), while the average stood at $20.7 million.
  • Data for Amicus Therapeutics' Non-Current Deffered Revenue shows a maximum YoY declined of 29.75% (in 2012) over the last 5 years.
  • Quarterly analysis of 4 years shows Amicus Therapeutics' Non-Current Deffered Revenue stood at $42.6 million in 2009, then reached $25.6 million in 2010, then declined by 25.90% to $19.0 million in 2011, then fell by 29.75% to $15.7 million in 2012.
  • Its last three reported values are $15.7 million in Q2 2012, $17.3 million for Q1 2012, and $19.0 million during Q4 2011.